What is Metformin used for and how does it work?

Metformin is a first-line drug for type 2 diabetes, used for over 50 years. It primarily inhibits complex one of the mitochondria, reducing the liver's glucose output. Its broader mechanisms beyond glucose lowering are still debated.

How does insulin resistance develop in type 2 diabetes?

Insulin resistance begins in muscles where accumulating intramuscular fat (triacylglycerides and diacylglycerides) interrupts the insulin signaling pathway, requiring more insulin to transport glucose into cells. This eventually affects the liver and pancreas, leading to elevated glucose levels and impaired insulin production.

What are the common causes of insulin resistance?

Major causes include energy imbalance (excess fat accumulation), inactivity, sleep deprivation (which can reduce glucose disposal by half in a week), and hypercortisolemia.

Is Berberine a good alternative to Metformin?

Berberine is referred to as 'the poor man's Metformin' because it has similar properties, such as reducing mTOR and blood glucose. Peter Attia had mixed personal experiences with it, experiencing headaches from hypoglycemia if not enough carbohydrates were ingested after taking it.

What does 'geroprotection' mean in the context of drugs like Metformin?

Geroprotection refers to the idea that a drug can provide protection from aging itself, targeting broad 'hallmarks of aging' rather than a specific disease of aging. Examples include decreased autophagy, increased senescence, and genomic instability.

What was the key limitation of the original Banister study on Metformin?

A significant limitation was 'informative censoring,' where patients on Metformin who progressed to more severe diabetes or stopped the drug were excluded. This could artificially inflate the perceived benefits of Metformin by removing sicker individuals from the analysis.

What did the Keys paper find when re-evaluating Metformin's survival advantage?

The Keys paper, using a larger Danish registry and a more rigorous twin-control methodology, found no survival advantage for Metformin in type 2 diabetics that undid the disadvantage of having diabetes. In fact, diabetic patients on Metformin had a significantly higher chance of dying compared to non-diabetic controls, even after various adjustments.

Why is the Interventions Testing Program (ITP) considered the 'gold standard' for animal longevity studies?

The ITP is highly rigorous, using non-inbred mouse strains, conducting concurrent tests in three different labs with large sample sizes, and testing molecules specifically for geroprotection.

Does short-term caloric restriction offer longevity benefits?

Peter Attia believes short periods of caloric restriction (e.g., a few days of fasting) are likely not sufficient to trigger significant longevity benefits, and even longer periods can lead to muscle mass loss which is difficult to regain.

What is Dr. Huberman's suggested method for critically reading scientific papers?

Dr. Huberman recommends identifying the general and specific research questions, understanding the approach/methods used, noting what was found (often from figure headers), and critically asking if the conclusions are truly substantiated by the findings and methods.

How do 'belief effects' differ from 'placebo effects'?

Placebo effects are binary (on/off, drug/no drug), while belief effects are scaled based on the amount and type of information received about a substance or intervention. Belief effects can measurably shift physiology, not just subjective experience.

How does nicotine enhance cognitive performance?

Nicotine binds to nicotinic acetylcholine receptors in key brain areas (like the basal forebrain, locus ceruleus, and pedunculopontine nucleus). This increases the signal-to-noise ratio of sensory information in the thalamus, improving attention and clarity.

What did the nicotine-belief study on bioRxiv reveal about brain activation?

The study showed that smokers who were told they received high doses of nicotine (but all received the same low dose) exhibited higher activation in attention-related thalamic regions and stronger connectivity between the thalamus and the ventromedial prefrontal cortex, demonstrating that belief can dose-dependently modulate brain physiology.

What is the 'nocebo effect'?

The nocebo effect is when negative expectations or beliefs about a treatment's side effects lead to the actual experience of those side effects. It's the inverse of the placebo effect, where belief in harm contributes to adverse outcomes.

Key Moments

270 ‒ Journal club with Andrew Huberman: metformin, power of belief, & how to read scientific papers

Peter Attia MD

Science & Technology4 min read132 min video

Sep 11, 2023|55,696 views|1,169|107

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

TL;DR

Two papers: Metformin may not offer survival benefits; belief influences drug effects.

Key Insights

The Keys et al. study re-analyzed Metformin's survival benefits, finding no advantage in diabetics compared to controls, contrasting with earlier findings.

Early Metformin trials like Bannister's may have excluded too many progressing or non-compliant patients, skewing results towards a positive survival bias.

Belief effects, distinct from placebo, show that expectations about drug dosage (even with identical doses) can alter physiological responses, particularly in brain activation.

The paper on belief and nicotine demonstrated that perceived dose influenced thalamic activation and the thalamic-prefrontal cortex pathway, impacting task performance.

Limitations in the belief study include small sample size and the absence of a zero-nicotine control group, preventing definitive conclusions for non-smokers.

The discussion highlights the challenges in interpreting epidemiological studies due to confounding factors like medication use and the importance of randomized controlled trials.

Biomarkers for aging and the impact of interventions remain a significant gap in longevity research, hindering precise measurement of treatment efficacy.

Strategies for parsing scientific papers, such as identifying the core question, approach, findings, and conclusion, are crucial for critical evaluation.

RE-EVALUATING METFORMIN'S SURVIVAL ADVANTAGE

The conversation begins by dissecting a study by Keys and colleagues that reassessed evidence for Metformin's survival advantage in type 2 diabetics. Unlike earlier, highly influential work by Bannister et al. (2014), which suggested Metformin conferred a survival benefit, the newer study, using a larger Danish health registry and a discordant twin analysis, found no such advantage. The participants on Metformin with diabetes showed no improved survival compared to matched controls without diabetes. This challenges previous interpretations and highlights the potential impact of study design and patient selection criteria, particularly the exclusion of patients who progressed or stopped the medication.

METHODOLOGICAL CHALLENGES IN EPIDEMIOLOGICAL STUDIES

Both studies discussed underscore the inherent difficulties in epidemiological research. The Bannister study's use of 'informative censoring'—excluding patients who progressed to more significant drug regimens—is identified as a potential bias. The Keys study attempted to mitigate this by using both matched singletons and discordant twins. However, even with sophisticated matching for demographics and health status, significant confounding factors, such as differences in medication usage (lipid-lowering, antihypertensives, etc.), remain difficult to fully control for, making it challenging to isolate the effect of Metformin itself.

THE PROFOUND INFLUENCE OF BELIEF ON PHYSIOLOGY

Shifting gears, the discussion moves to a pre-print study investigating 'belief effects,' which are distinguished from traditional placebo effects. This research explored how individuals' expectations about the dose of a drug—in this case, nicotine—can alter their physiological responses, even when the actual dose is identical across groups. Participants were given the same low dose of nicotine via vaping but were told they received low, medium, or high doses. Their subjective experience and, more critically, their brain activation patterns (particularly in the thalamus and its connections to the prefrontal cortex) scaled according to their belief about the dose.

NICOTINE, BRAIN RESPONSES, AND DOSE-DEPENDENT BELIEFS

The findings on nicotine are particularly striking. While the subjective belief about nicotine strength correlated with self-reported experience, the study revealed its impact on brain regions associated with attention and sensory processing. The thalamus, known to be influenced by nicotinic acetylcholine receptors, showed a dose-dependent activation pattern that mirrored the participants' beliefs, not the actual nicotine levels. Interestingly, the reward pathways (dopamine release) were not modulated by belief, suggesting belief effects might act through different neural circuits than direct drug pharmacology.

IMPLICATIONS FOR DRUG THERAPY AND INTERPRETATION

The implications of these belief effects are far-reaching, extending beyond nicotine to various drug interventions, including antidepressants, vaccines, and even behavioral therapies. The study suggests that what patients believe about a drug's dosage and expected effects can measurably influence its physiological impact. This could explain why some individuals respond differently and highlights the potential for optimizing therapeutic outcomes by managing patient expectations. It also underscores the difficulty in interpreting clinical trial data, where subjective beliefs may interact with pharmacological actions.

NAVIGATING SCIENTIFIC LITERATURE AND FUTURE RESEARCH

The conversation concludes with a meta-discussion on how to critically read and interpret scientific papers. Both hosts emphasize the importance of understanding the study's question, methodology, findings, and conclusions, while also considering limitations and potential biases. The lack of robust biomarkers for aging and the difficulty in measuring the impact of longevity interventions are identified as major hurdles. The ongoing 'TAME' trial for Metformin and the need for well-designed prospective studies are mentioned as crucial steps toward resolving complex questions about drug efficacy and aging.

Mentioned in This Episode

●Supplements

●Products

●Software & Apps

●Organizations

●Books

●Studies Cited

●Concepts

●People Referenced

Common Questions

The purpose is to analyze scientific papers, understand their findings, dissect information like scientists and clinicians, and critically evaluate methodologies (good, bad, and ugly).